Clinical Trial Update: Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients [Phase 3]

View source ↗

Summary

Acalabrutinib safety study in untreated and relapsed or refractory chronic lymphocytic leukemia patients (Phase 3) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED